Precision medicine for prostate cancer—improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier

Abstract

A multiplex 6-gene copy number classifier was used to distinguish between low-or intermediate-risk prostate cancer patients. The study analysed a cohort of 448 patients and previously published datasets from radical prostatectomies. The classifier performs better than conventional stratification methods, is low cost, and can be performed easily in clinical laboratories.

Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies

“…The understanding and management of prostate cancer have evolved significantly over the years. Today, due to enhanced screening methods and more effective treatments, survival rates for prostate cancer are generally high, particularly for localized forms of the disease [ 19 , 20 ]. However, aggressive and late-stage forms, such as CRPC, present ongoing challenges that researchers are striving to address.…”